Screener
Jade Biosciences JBIO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $55,085 | $88,438 |
| Investments | 256,210 | 247,720 |
| Prepaid expenses and other current assets | 7,222 | 12,658 |
| Total current assets | 318,517 | 348,816 |
| Property and equipment, net | 157 | 170 |
| Operating lease right-of-use asset | 690 | 726 |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's cash & equivalents?
- Jade Biosciences (JBIO) reported cash & equivalents of $55.09M in Q1 2026.
- How has Jade Biosciences's cash & equivalents changed year-over-year?
- Jade Biosciences's cash & equivalents increased by 24.6% year-over-year, from $44.22M to $55.09M.
- What is the long-term trend for Jade Biosciences's cash & equivalents?
- Over 5 years (2020 to 2025), Jade Biosciences's cash & equivalents has grown at a 80.6% compound annual growth rate (CAGR), from $4.6M to $88.44M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Jade Biosciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude